Table 2.
PROMISE-EPI participants interviewed | PROMISE-EPI participants not interviewed | P value | ||
---|---|---|---|---|
N = 80a | N = 1262 | |||
Intervention arm | 49 (61.3%) | 619 (49%) | 0.038 | |
Mothers | ||||
Age | mean (sd) | 30.0 (6.5) | 30.5 (5.9) | 0.47 |
Time of HIV diagnosis | Before this last pregnancy | 53 (66.3%) | 899/1260 (71.3%) | 0.37 |
During/after this last pregnancy | 27 (33.8%) | 361/1260 (28.7%) | ||
Mothers taking ART | 76 (95.0%) | 1243 (98.5%) | 0.044 | |
Highest level of education | None | 5 (6.3%) | 82 (6.5%) | 0.87 |
Primary | 29 (36.3%) | 494 (39.1%) | ||
Secondary or more | 46 (57.5%) | 686 (54.4%) | ||
Employment situation during pregnancy | Not working | 56 (70.0%) | 872 (69.1%) | 0.61 |
Working (formal sector) | 5 (6.3%) | 122 (9.7%) | ||
Working (informal sector) | 17 (21.3%) | 248 (19.7%) | ||
Studying | 2 (2.5%) | 20 (1.6%) | ||
Marital status | Married/cohabitating | 63 (78.8%) | 1,047 (83.0%) | 0.43 |
Single | 15 (18.8%) | 173 (13.7%) | ||
Divorced/separate/widowed | 2 (2.5%) | 42 (3.3%) | ||
HIV Status known by partner | No | 7/71 (9.9%) | 88/974 (9.0%) | 0.29 |
Yes | 60/71 (84.5%) | 858/974 (88.1%) | ||
Not applicable (no partner) | 4/71 (5.6%) | 28/974 (2.9%) | ||
Maternal VL > = 1000cp/mL at EPI-2 (both arms) | 38 (47.5%) | 105/1222 (8.6%) | < 0.001 | |
Maternal VL > = 1000cp/mL at M6 | 23/76 (30.3%) | 64/1054 (6.1%) | < 0.001 | |
Still breastfeeding at M12 | 63/79 (79.7%) | 734/990 (74.1%) | 0.35 | |
Infants | ||||
Sex | Female | 40 (50.0%) | 611 (48.4%) | 0.82 |
Six week PNP at birth (3 drugs) | 74 (92.5%) | 1217/1262 (96.4%) | 0.12 | |
Infant eligible to lamivudine at EPI-2 (intervention arm) | 35 (43.8%) | 37 (2.9%) | < 0.001 | |
Newly eligible to lamivudine at M6 (mother on the intervention arm newly unsuppressed) | 3 (3.8%) | 13 (1.0%) | 0.065 |
ART Antiretroviral therapy, VL Viral load, PNP Post-natal-prophylaxis, EPI-2 second visit of the expanded program on immunization
a The PROMISE-EPI identifier was not recorded for one PROMISE-EPI participant